TCM
ABBV icon

Triumph Capital Management’s AbbVie ABBV Stock Holding History

Triumph Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$282K Sell
1,121
-77
-6% -$16.6K 0.05% 313
2026
Q1 		$260K Buy
1,198
+8
+0.7% +$1.77K 0.05% 295
2025
Q4 		$272K Buy
+1,190
New +$271K 0.06% 267
2025
Q2 		– Sell
-1,019
Closed -$213K – 287
2025
Q1 		$213K Buy
+1,019
New +$198K 0.07% 256

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Triumph Capital Management's ABBV Position: Q2 2026 in Review

Triumph Capital Management reduced its AbbVie (ABBV) stake by 6.4% in Q2 2026, selling an estimated $16.6K and leaving 1,121 shares worth $282K. The position accounts for 0.05% of the portfolio, ranked #313.

Triumph Capital Management first reported a position in ABBV in Q1 2025 and has held it in 4 quarters since. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Triumph Capital Management held 1,121 shares of AbbVie worth $282K as of Q2 2026.
  • Triumph Capital Management sold 77 AbbVie shares in Q2 2026, an estimated $16.6K.
  • AbbVie made up 0.05% of Triumph Capital Management's portfolio in Q2 2026, its #313 holding.
  • Triumph Capital Management first reported a position in AbbVie in Q1 2025 and has held it in 4 quarters since.
  • 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.